Podcasts about Danaher

Eric Topol (00:05):Hello, it's Eric Topol from Ground Truths, and I've got some really exciting stuff to talk to you about today. And it's about the announcement for a new Center for pediatric CRISPR Cures. And I'm delight to introduce doctors Jennifer Doudna and Priscilla Chan. And so, first let me say this is amazing to see this thing going forward. It's an outgrowth of a New England Journal paper and monumental report on CRISPR in May. [See the below post for more context]Let me introduce first, Dr. Doudna. Jennifer is the Li Ka Shing Chancellor's Chair and a Professor in the departments of chemistry and of molecular and cell biology at the University of California Berkeley. She's also the subject of this book, one of my favorite books of all time, the Code Breaker. And as you know, the 2020 Nobel Prize laureate for her work in CRISPR-Cas9 genome editing, and she founded the Innovative Genomics Institute (IGI) back 10 years ago. So Jennifer, welcome.Jennifer Doudna (01:08):Thank you, Eric. Great to be here.Eric Topol (01:10):And now Dr. Priscilla Chan, who is the co-founder of the Chan Zuckerberg Initiative (CZI) that also was started back in 2015. So here we are, a decade later, these two leaders. She is a pediatrician having trained at UCSF and is committed to the initiative which has as its mission statement, “to make it possible to cure, prevent, and manage all diseases in this century.” So today we're going to talk about a step closer to that. Welcome, Priscilla.Priscilla Chan (01:44):Thank you. Thanks for having me.Eric Topol (01:46):Alright, so I thought we'd start off by, how did you two get together? Have you known each other for over this past decade since you both got all your things going?Jennifer Doudna (01:56):Yes, we have. We've known each other for a while. And of course, I've admired the progress at the CZI on fundamental science. I was an advisor very early on and I think actually that's how we got to know each other. Right, Priscilla?Priscilla Chan (02:11):Yeah, that's right. We got to know each other then. And we've been crisscrossing paths. And I personally remember the day you won the Nobel Prize. It was in the heart of the pandemic and a lot of celebrations were happening over Zoom. And I grabbed my then 5-year-old and got onto the UCSF celebration and I was like, look, this is happening. And it was really cool for me and for my daughter.Eric Topol (02:46):Well, it's pretty remarkable convergence leading up to today's announcement, but I know Priscilla, that you've been active in this rare disease space, you've had at CZI a Rare As One Project. Maybe you could tell us a bit about that.Priscilla Chan (03:01):Yeah, so at CZI, we work on basic science research, and I think that often surprises people because they know that I'm a pediatrician. And so, they often think, oh, you must work in healthcare or healthcare delivery. And we've actually chosen very intentionally to work in basic science research. In part because my training as a pediatrician at UCSF. As you both know, UCSF is a tertiary coronary care center where we see very unusual and rare cases of pediatric presentations. And it was there where I learned how little we knew about rare diseases and diseases in general and how powerful patients were. And that research was the pipeline for hope and for new discoveries for these families that often otherwise don't have very much access to treatments or cures. They have a PDF that maybe describes what their child has. And so, I decided to invest in basic science through CZI, but always saw the power of bringing rare disease patient cohorts. One, because if you've ever met a parent of a child with rare disease, they are a force to be reckoned with. Two, they can make research so much better due to their insights as patients and patient advocates. And I think they close the distance between basic science and impact in patients. And so, we've been working on that since 2019 and has been a passion of ours.Eric Topol (04:40):Wow, that's great. Now Jennifer, this IGI that you founded a decade ago, it's doing all kinds of things that are even well beyond rare diseases. We recently spoke, I know on Ground Truths about things as diverse as editing the gut microbiome in asthma and potentially someday Alzheimer's. But here you were very much involved at IGI with the baby KJ Muldoon. Maybe you could take us through this because this is such an extraordinary advance in the whole CRISPR Cures story.Jennifer Doudna (05:18):Yes, Eric. It's a very exciting story and we're very, very proud of the teamwork that went into making it possible to cure baby KJ of his very rare disease. And in brief, the story began back in August of last year when he was born with a metabolic disorder that prevented him from digesting protein, it's called a urea cycle disorder and rare, but extremely severe. And to the point where he was in the ICU and facing a very, very difficult prognosis. And so, fortunately his clinical team at Children's Hospital of Philadelphia (CHOP) reached out to Fyodor Urnov, who is the Director of Translational Medicine at the IGI here in the Bay Area. They teamed up and realized that they could quickly diagnose that child because we had an IRB approved here at the IGI that allowed us to collect patient samples and do diagnosis. So that was done.Jennifer Doudna (06:26):We created an off-the-shelf CRISPR therapy that would be targeted to the exact mutation that caused that young boy's disease. And then we worked with the FDA in Washington to make sure that we could very safely proceed with testing of that therapy initially in the lab and then ultimately in two different animal models. And then we opened a clinical trial that allowed that boy to be enrolled with, of course his parents' approval and for him to be dosed and the result was spectacular. And in fact, he was released from the hospital recently as a happy, healthy child, gaining lots of weight and looking very chunky. So it's really exciting.Eric Topol (07:16):It's so amazing. I don't think people necessarily grasp this. This timeline [see above] that we'll post with this is just mind boggling how you could, as you said Jennifer, in about six months to go from the birth and sequencing through cell specific cultures with the genome mutations through multiple experimental models with non-human primates even, looking at off-target effects, through the multiple FDA reviews and then dosing, cumulatively three dosing to save this baby's life. It really just amazing. Now that is a template. And before we go to this new Center, I just wanted to also mention not just the timeline of compression, which is unimaginable and the partnership that you've had at IGI with I guess Danaher to help manufacture, which is just another part of the story. But also the fact that you're not just even with CRISPR 1.0 as being used in approvals previously for sickle cell and β-thalassemia, but now we're talking about base editing in vivo in the body using mRNA delivery. So maybe you could comment on that, Jennifer.Jennifer Doudna (08:38):Yeah, very good point. So yeah, we used a version of CRISPR that was created by David Liu at the Broad Institute and published and available. And so, it was possible to create that, again, targeted to the exact mutation that caused baby KJ's disease. And fortunately, there was also an off-the-shelf way to deliver it because we had access to lipid nanoparticles that were developed for other purposes including vaccinations. And the type of disease that KJ suffered from is one that is treatable by editing cells in the liver, which is where the lipid nanoparticle naturally goes. So there were definitely some serendipity here, but it was amazing how all of these pieces were available. We just had to pull them together to create this therapy.Eric Topol (09:30):Yeah, no, it is amazing. So that I think is a great substrate for starting a new Center. And so, maybe back to you Priscilla, as to what your vision was when working with Jennifer and IGI to go through with this.Priscilla Chan (09:45):I think the thing that's incredibly exciting, you mentioned that at CZI our mission is to cure, prevent, and manage all disease. And when we talked about this 10 years ago, it felt like this far off idea, but every day it seems closer and closer. And I think the part that's super exciting about this is the direct connection between the basic science that's happening in CRISPR and the molecular and down to the nucleotide understanding of these mutations and the ability to correct them. And I think many of us, our imaginations have included this possibility, but it's very exciting that it has happened with baby KJ and CHOP. And we need to be able to do the work to understand how we can treat more patients this way, how to understand the obstacles, unblock them, streamline the process, bring down the cost, so that we better understand this pathway for treatment, as well as to increasingly democratize access to this type of platform. And so, our hope is to be able to do that. Take the work and inspiration that IGI and the team at CHOP have done and continue to push forward and to look at more cases, look at more organ systems. We're going to be looking in addition to the liver, at the bone marrow and the immune system.Priscilla Chan (11:17):And to be able to really work through more of the steps so that we can bring this to more families and patients.Eric Topol (11:30):Yeah, well it's pretty remarkable because here you have incurable ultra-rare diseases. If you can help these babies, just think of what this could do in a much broader context. I mean there a lot of common diseases have their roots with some of these very rare ones. So how do you see going forward, Jennifer, as to where you UC Berkeley, Gladstone, UCSF. I'm envious of you all up there in Northern California I have to say, will pull this off. How will you get the first similar case to KJ Muldoon going forward?Jennifer Doudna (12:13):Right. Well, IGI is a joint institute, as you probably know, Eric. So we were founded 10 years ago as a joint institute between UC Berkeley and UCSF. And now we have a third campus partner, UC Davis and we have the Gladstone Institute. So we've got an extraordinary group of clinicians and researchers that are coming together for this project and the Center to make it a success. We are building a clinical team at UCSF. We have several extraordinary leaders including Jennifer Puck and Chris Dvorak, and they are both going to be involved in identifying patients that could be enrolled in this program based on their diagnosis. And we will have a clinical advisory group that will help with that as well. So we'll be vetting patients probably right after we announce this, we're going to be looking to start enrolling people who might need this type of help.Eric Topol (13:18):Do you think it's possible to go any faster right now than the six months that it took for KJ?Jennifer Doudna (13:26):I think it could be. And here's the reason. There's a very interesting possibility that because of the type of technology that we're talking about with CRISPR, which fundamentally, and you and I have talked about this previously on your other podcast. But we've talked about the fact that it's a programmable technology and that means that we can change one aspect of it, one piece of it, which is a piece of a molecule called RNA that's able to direct CRISPR to the right sequence where we want to do editing and not change anything else about it. The protein, the CRISPR protein stays the same, the delivery vehicle stays the same, everything else stays the same. And so, we're working right now with FDA to get a platform designation for CRISPR that might allow streamlining of the testing process in some cases. So it'll obviously come down to the details of the disease, but we're hopeful that in the end it will be possible. And Priscilla and I have talked about this too, that as AI continues to advance and we get more and more information about rare diseases, we'll be able to predict accurately the effects of editing. And so, in some cases in the future it may be possible to streamline the testing process even further safely.Eric Topol (14:51):And I also would note, as you both know, well this administration is really keen on genome editing and they've had a joint announcement regarding their support. And in my discussions with the FDA commissioner, this is something they are very excited about. So the timing of the new Center for pediatric CRISPR Cures is aligned with the current administration, which is good to see. It's not always the case. Now going back, Priscilla, to your point that not just for the liver because delivery has been an issue of course, and we're going to try to get after a lot of these really rare diseases, it's going to go beyond there. So this is also an exciting new dimension of the Center, as you said, to go after the bone marrow for hematopoietic cells, perhaps other organs as well.Priscilla Chan (15:42):I mean what the expertise and feasibility, the immune system is going to be the next target. Jennifer Puck has been a pioneer in this work. She's the one who designed the newborn screen that will be the tool that picks up these patients as they are born. And I think the thing that's tremendous is the immune system, first of all is active in many, many diseases, not just these cases of children born with partial or absence of immune systems. And the course right now that these babies are left with is complete isolation and then a very long and arduous course of a bone marrow transplant with high morbidity and mortality. And even if after the transplant you have complications like graft versus host and immunosuppression. And so, the idea of being able to very specifically and with less the conditioning and morbidity and mortality of the treatment, being able to address this is incredible. And the implications for other diseases like blood cancers or other hematopoietic diseases, that's incredible. And that actually has an incredibly broad base of patients that can benefit from the learnings from these babies with severe combined immunodeficiencies.Eric Topol (17:10):Yeah, I think that goes back to a point earlier maybe to amplify in that previous CRISPR generation, it required outside the body work and it was extremely laborious and time consuming and obviously added much more to the expense because of hospitalization time. This is different. This is basically doing this inside the affected patient's body. And that is one of the biggest reasons why this is a big step forward and why we're so fortunate that your Center is moving forward. Maybe before we wrap up, you might want to comment, Jennifer on how you were able to bring in to build this platform, the manufacturing arm of it, because that seems to be yet another dimension that's helpful.Jennifer Doudna (18:01):Indeed, yes. And we were again fortunate with timing because you mentioned briefly that the IGI had set up a program with the Danaher Corporation back in January of last year. We call it our Beacon project. And it's focused on rare disease. And it's a really interesting kind of a unique partnership because Danaher is a manufacturing conglomerate. So they have companies that make molecules, they make proteins, they make RNA molecules, they make delivery molecules. And so, they were excited to be involved with us because they want to be a provider of these types of therapies in the future. And they can see the future of CRISPR is very exciting. It's expanding, growing area. And so, that agreement was in place already when the baby KJ case came to our attention. And so, what we're hoping to do with Danaher is again, work with them and their scientists to continue to ask, how can we reduce the cost of these therapies by reducing the cost of the molecules that are necessary, how to make them efficiently. We already, it's very interesting, Fyodor Urnov has toured their plant in North Dakota recently, and he found in talking to their engineers, there are a number of things that we can already see will be possible to do that are going to make the process of manufacturing these molecules faster and cheaper by a lot.Eric Topol (19:28):Wow.Jennifer Doudna (19:28):So it's a win-win for everybody. And so, we're really excited to do that in the context of this new Center.Eric Topol (19:36):Oh, that's phenomenal because some of these disorders you don't have that much time to work with before they could be brain or organ or vital tissue damage. So that's great to hear that. What you built here is the significance of it can't be under emphasized, I'll say because we have this May report of baby KJ, which could have been a one-off and it could have been years before we saw another cure of an ultra-rare disorder. And what you're doing here is insurance against that. You're going to have many more cracks at this. And I think this is the excitement about having a new dedicated Center. So just in closing, maybe some remarks from you Priscilla.Priscilla Chan (20:24):I just want to emphasize one point that's really exciting as we talk about these ultra-rare cases that they're often like one in a million. All these learnings actually help maximize the impact of lots of research across the sector that impacts actually everyone's health. And so, our learnings here from these patients that have very significant presentations that really can stand to benefit from any treatment is hopefully paving the way for many, many more of us to be able to live healthier, higher quality lives through basic science.Eric Topol (21:13):And over to you, Jennifer.Jennifer Doudna (21:15):Couldn't agree more. It's a really interesting moment. I think what we hope we are, is we're at sort of an inflection point where, as I mentioned earlier, all the pieces are in place to do this kind of therapeutic and we just need a team that will focus on doing it and pulling it together. And also learning from that process so that as Priscilla just said, we are ultimately able to use the same strategy for other diseases and potentially for diseases that affect lots of people. So it's exciting.Eric Topol (21:46):For sure. Now, if I could just sum up, this is now a decade past the origination of your work of CRISPR and how already at the first decade culminated in sickle cell disease treatment and β-thalassemia. Now we're into the second decade of CRISPR. And look what we've seen, something that was unimaginable until it actually happened and was reported just a little over a month ago. Now going back to Priscilla's point, we're talking about thousands of different rare Mendelian genomic disorders, thousands of them. And if you add them all up of rare diseases, we're talking about hundreds of millions of people affected around the world. So this is a foray into something much bigger, no less the fact that some of these rare mutations are shared by common diseases and approaches. So this really big stuff, congratulations to both of you and your organizations, the Innovative Genomics Institute and the Chan Zuckerberg Initiative for taking this on. We'll be following it with very deep interest, thank you.****************************************************Thanks for listening, reading and subscribing to Ground Truths.If you found this interesting PLEASE share it!That makes the work involved in putting these together especially worthwhile.Thanks to Scripps Research, and my producer, Jessica Nguyen, and Sinjun Balabanoff for video/audio support.All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. Get full access to Ground Truths at erictopol.substack.com/subscribe

00:00 - 07:00 - Introduction, getting start at BJJ and social media 07:00 - 13:00 - Strength training and cults 13:00 - 15:15 - Conditioning15:15 - 24:10 - Understanding S&C for competitive sports24:10 - 29:00 - Understanding conditioning for BJJ 29:00 - 32:24 - MMA32:24 - 36:30 - Romans early days & Jiu Jitsu journey 36:30 - 45:00 - Training with Danaher and scheduling Jiu Jitsu 45:00 - 48:45 - Improving your Jiu Jitsu 48:45 - 56:00 - Competition VS Training room mindset56:00 - 57:33 - Closing notes Sponsors:Progress: https://www.progressjj-europe.com Use code RUNESCAPE at checkout for discount on any productsLess Impressed More Involved: https://outlierdb.com/ - use code RUNESCAPE for 50% off your first monthHow to work with us:Where to find Roman: https://www.instagram.com/romanjiujitsu/ Charles Strength Training Programs GET 7 DAY FREE MAT STRONG PROGRAM: https://mailchi.mp/charlesallanprice/mat-strong-landing-page BJJ Workouts Instructional: https://bjjfanatics.com/collections/new-releases/products/building-workouts-for-bjj-by-charles-allan-price 1:1 Coaching Inquiries: https://7kdbbkmkmsl.typeform.com/to/nSZHpCOL Hosted on Acast. See acast.com/privacy for more information.

In this episode, I'm joined by one of the most original and dynamic minds in Jiu-Jitsu today — Daniel Schuardt.A black belt competitor and coach currently training under John Danaher with the New Wave / Kingsway team in Austin, Texas, Daniel is the perfect blend of high-level athlete, thoughtful instructor, and unapologetically weird internet personality — and I mean that in the best way. He's also the head coach at Precision MMA in Australia.Daniel has competed around the globe, recently grabbing headlines with a dominant AIGA win. But what really sets Daniel apart is his ability to make the complicated stuff digestible — and hilarious. Whether he's explaining guard retention, breaking down strategy, or posting bizarre memes, Daniel keeps it real. His Instagram, @daniel_the_manchild, is a must-follow for anyone serious about learning while laughing.In this episode, we get into competition mindset, teaching methodology, training in the Danaher room, making Jiu-Jitsu more human and less dogmatic, and why being curious and creative on the mats can be a superpower.Links:https://www.instagram.com/daniel_the_manchild/⁠⁠https://www.instagram.com/precision_mma_official/⁠⁠https://www.precisionmma.com.au/⁠Buy Salt Electrolytes  @SaltElectrolytes  use code FWB for 15% off. https://saltelectrolytes.com/?fwb Become a VIP member for only .99 a month, get ad-free, uncensored, early episodes https://is.gd/GytgXMInstagram @foreverwhitebeltshow.Go buy your Forever White Belt swag at teespring.com/forever-white-belt.Linktree https://linktr.ee/foreverwhitebelt

Mark DeLuzio discusses the intangibles that made all the difference to the success of the Danaher Business System. He also discussed the main ingredients of DBS, the 5Ps: Purpose, Principles, People, Plan, Process.

What is PSNFL? Find out on this week's PlayingFTSE Show!It's been a storming week for both Steves. But who's done well, who's done better, and what's been going on with Nintendo?Rachel Reeves has issued the latest set of government spending plans. And there have been some obvious winners from the news. Chief among these is Rolls-Royce. But the housebuilders have also been doing well and both Steves are actually relatively optimistic about the plans going forward.On the face of it, Halma's latest results appear to be outstanding and the stock is up as a result. Steve W has been having a look at the numbers.Organic growth is impressive and the stock market clearly likes it. However, with a March 31st cutoff, could there be tariff volatility on the way?Wise might be leaving the UK, but Steve and Steve aren't willing to let this one go easily. Another outstanding year has seen the company go from strength to strength.More people, more transaction volume, and lower charges are seeing the company pull away. So is it likely to attract a better multiple on the other side of the Atlantic?Danaher is an S&P 500 stock that we haven't talked about much before. But it's the kind of business that both Steves like – strong growth and a good acquirer. It has a very interesting backstory and a culture that gives it a big competitive advantage. So at a cyclical low, could it be a stock to buy right now?Only on this week's PlayingFTSE Podcast!► Get a free share!This show is sponsored by Trading 212! To get free fractional shares worth up to 100 EUR / GBP, you can open an account with Trading 212 through this link https://www.trading212.com/Jdsfj/FTSE. Terms apply.When investing, your capital is at risk and you may get back less than invested.Past performance doesn't guarantee future results.► Get 15% OFF Finchat.io:Huge thanks to our sponsor, FinChat.io, the best investing toolkit we've discovered! Get 15% off your subscription with code below and unlock powerful tools to analyze stocks, discover hidden gems, and build income streams. Check them out at FinChat.io!https://finchat.io/playingftse/?lmref=iQl2VQ► Follow Us On Substack:https://playingftse.substack.com/► Support the show:Appreciate the show and want to offer your support? You could always buy us a coffee at: https://ko-fi.com/playingftse(All proceeds reinvested into the show and not to coffee!)There are many ways to help support the show, liking, commenting and sharing our episodes with friends! You can also check out our clothing merch store: https://playingftse.teemill.com/We get a small cut of anything you buy which will be reinvested back into the show...► Timestamps:0:00 INTRO & OUR WEEKS10:13 REEVES SPENDING REVIEW24:21 HALMA36:52 WISE54:40 DANAHER► Show Notes:What's been going on in the financial world and why should anyone care? Find out as we dive into the latest news and try to figure out what any of it means. We talk about stocks, markets, politics, and loads of other things in a way that's accessible, light-hearted and (we hope) entertaining. For the people who know nothing, by the people who know even less. Enjoy► Wanna get in contact?Got a question for us? Drop it in the comments below or reach out to us on Twitter: https://twitter.com/playingftseshow Or on Instagram: https://www.instagram.com/playing_ftse/► Enquiries: Please email - playingftsepodcast@gmail(dot)com► Disclaimer: This information is for entertainment purposes only and does not constitute financial advice. Always consult with a qualified financial professional before making any investment decisions.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Nvidias neuen KI-Billigchip, Hoffen auf das Pharma-Revival und was diese Woche sonst noch wichtig wird. Außerdem geht es um VanEck Uranium and Nuclear Technologies ETF (WKN: A3D47K), Uranium Energy, Oklo, Nuscale, Health Care Select Sector SPDR (WKN: A14QB2), CVS Health, United Health Group, Eli Lilly, Cigna, Danaher, Thermo Fisher Scientific sowie Gilead, Sandoz, J&J, Roche, Sanofi, VanEck Quantum Computing ETF (WKN: A418QM) Google, IBM, Microsoft, Sony, Boeing, Honeywell, IonQ, Rigetti und D-Wave. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

rWotD Episode 2942: Travis Stevens Welcome to Random Wiki of the Day, your journey through Wikipedia's vast and varied content, one random article at a time.The random article for Saturday, 24 May 2025, is Travis Stevens.Travis Stevens (born February 28, 1986) is an American judoka who competed in the 2008, 2012, and 2016 Summer Olympics. He competes in the men's half-middleweight (−81 kg) division. On August 9, 2016, Stevens became the third American male judoka to win a silver medal in the Olympics.Stevens also holds a black belt in Brazilian jiu-jitsu under John Danaher and Renzo Gracie, which Danaher awarded on November 19, 2013.This recording reflects the Wikipedia text as of 00:09 UTC on Saturday, 24 May 2025.For the full current version of the article, see Travis Stevens on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Mastodon at @wikioftheday@masto.ai.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm neural Stephen.

What You'll Learn:In this episode, hosts Catherine McDonald, Patrick Adams, and guest Olaf Boettger discuss the importance of coaching for success, particularly in developing and mentoring emerging leaders. They highlight the need for leaders to unlearn harmful behaviors and adapt to new leadership styles.About the Guest:With 26 years of experience in Continuous Improvement, our guest brings a wealth of knowledge and a unique perspective shaped by leadership roles at two of the world's most respected organizations: Procter & Gamble and Danaher. He spent 10 years at P&G, including time as a Brand Manager, and 16 years at Danaher, where he served in a variety of critical roles. His expertise spans over three core areas, Business Leadership, Continuous Improvement Leadership, and Executive Coaching. Whether driving operational excellence, leading transformation, or coaching executives, he brings a powerful blend of strategy, systems thinking, and people development to the table.Links:Click Here For Olaf Boettger LinkedIn

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit Flatrate und Zinsen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. RTX & Northrop enttäuschen. 3M und Danaher performen. First Solar & T1 feiern Solar-Zölle. Finanzminister macht Hoffnung. Helvetia & Baloise, KKR & Biotage, Thoma Bravo & Boeing machen Deals. Sonst: Roche, Gold, Bitcoin, Tesla & SAP. Wenn du das hier liest, nutzt du mit hoher Wahrscheinlichkeit ein Produkt von Universal Display (WKN: 917585). BP (WKN: 850517) hat einen Aktivisten, Übernahmegerüchte und einfache Kurstreiber. Diesen Podcast vom 23.04.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Wed, 23 Apr 2025 06:08:59 +0000 https://podcast9d261b.podigee.io/175-new-episode dddb7717333865d0a81e8bfee776a5a8 JETZT Gratis Telekom Aktie sichern, hier gehts zum Smartbroker+ : https://get.smartbrokerplus.de/aktientalk-gewinnspiel/?af_ad=&af_ad_id=&af_adset=&af_c_id=544089&af_sub1=1-22b61702-a62c-389d-809d-182ca60217b6-a94450&pid=ingenioustechnologies_int&af_adset_id=&af_channel=Affiliate&af_site_id=527207&af_sub2=&c=Aktientalk-Telekom&clickid=1-22b61702-a62c-389d-809d-182ca60217b6-a94450&iclid=1-22b61702-a62c-389d-809d-182ca60217b6-a94450&utm_campaign=527207_&utm_medium=affiliate&utm_source=Aktientalk-Telekom full no Michael Flender & Daniel Wassmer

Cramer says he expects this beaten-down FinTech stock to make a comeback. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

European bourses modestly lower; US futures attempt to pare back Monday's hefty losses.DXY flat, USD/JPY fails to sustain a move below 140, EUR/USD back on a 1.14 handle as USD bounces off lows.Modest UST & Bund divergence while Gilts lag and hit lows on BoE's Greene, who highlighted that wage growth remains "pretty high".Spot gold briefly tested USD 3,500/oz before waning; industrial commodities mostly firmer.Looking ahead, Canadian Producer Prices, US Richmond Fed Index, EZ Consumer Confidence. Speakers including ECB's Knot, de Guindos, BoE's Breeden, Fed's Jefferson, Harker, Kashkari, Kugler & Barkin, Supply from the US, Earnings from Tesla, Verizon, GE Aerospace, Lockheed Martin, Danaher & Elevance.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

APAC stocks traded mixed with most indices rangebound despite the sell-off on Wall St after President Trump renewed his criticism against Fed Chair Powell.European equity futures indicate a lower cash market open with Euro Stoxx 50 future down 0.5%.DXY has extended on recent downside with JPY the main beneficiary, EUR/USD is above the 1.15 mark.Bunds are rangebound on return from the long weekend, crude futures have continued the mild rebound from the prior day's trough.Looking ahead, highlights include Canadian PPPI, US Richmond Fed Index, EZ Consumer Confidence, ECB's Knot, de Guindos, BoE's Breeden, Fed's Jefferson, Harker, Kashkari, Kugler & Barkin, Supply from Germany & US.Earnings from SAP, Iberdrola, Tesla, Verizon, GE Aerospace, Lockheed Martin, Danaher & Elevance.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Danaher steht nach der Abspaltung von Veralto und mehreren Zukäufen im Biotechnologie-Segment vor einer Phase strategischer Neupositionierung. Unter der Leitung von CEO Rainer M. Blair verfolgt das Unternehmen das Ziel, durch den Fokus auf Biotech und Diagnostik neue Wachstumsimpulse zu setzen. Gleichzeitig belasten ein schwächerer Ausblick und enttäuschende Quartalszahlen die Kursentwicklung. Seit der Corona-Pandemie verzeichnete Danaher zunächst außergewöhnliche Umsatz- und Ergebniszuwächse, die maßgeblich vom temporären COVID-19-Geschäft profitierten. Mit dem Wegfall dieses Sondereffekts normalisieren sich die Kennzahlen, während Investoren den Erfolg der Neuausrichtung kritisch bewerten. Die Analyse beleuchtet die operative Entwicklung der vergangenen Jahre, die strategische Positionierung im Markt, die Rolle des Managements sowie die finanzielle Situation des Konzerns. Im Fokus stehen zudem die Entwicklung der Margen, der Cashflows und der Bewertung im historischen und sektoralen Vergleich. Ergänzend erfolgt eine technische Analyse, die die aktuelle charttechnische Ausgangslage einordnet. Danaher steht damit an einem Wendepunkt: Die Frage, ob der Wandel hin zu einem fokussierten Biotech- und Diagnostikkonzern gelingen kann, bleibt offen. Inhaltsverzeichnis00:00 Intro00:53 Langfristiger Chart: Danaher vs. vergangene Videos02:43 Danaher vs. S&P 500 vs. Gesundheits-ETF (XLV) vs. Sartorius vs. Thermo Fisher vs. Agilent vs. Abbott vs. Illumina03:22 Danaher: Geschäftsmodell05:04 Letze Quartalszahlen06:45 Übernahmen & Zukäufe09:04 Anteil an wiederkehrenden Einnahmen11:16 Burggraben: Danaher12:11 Inhaberschaft & CEO13:47 Umsatz- & Margen-Entwicklung vs. Video aus 202314:22 Umsatz nach Segment & Region16:27 Gewinn, Cashflow & Dividenden-Entwicklung vs. Video aus 202318:53 Bilanz-Überblick & Aktienrückkäufe20:53 Kennzahlen-Überblick (KGV)21:40 Dividenden-Rendite & -Entwicklung22:11 Unternehmensbewertung: Allianz vs. Video aus 202323:14 Chartanalyse: Danaher vs. Video aus 202324:27 Ist die Danaher Aktie ein Kauf?26:55 Disclaimer28:38 Danke fürs Einschalten! Zusammenarbeit anfragenhttps://www.maximilian-gamperling.de/termin/ Social Media- Instagram: https://www.instagram.com/maximilian_gamperling/- LinkedIn: https://www.linkedin.com/in/gamperling/- Newsletter: https://www.maximilian-gamperling.de/newsletter- Podcast: https://akademie.maximilian-gamperling.de/podcasts/anker-aktien-podcast Meine Tools- Charts*: https://de.tradingview.com/?aff_id=117182- Aktienfinder: https://aktienfinder.net- Finchat.io*: https://finchat.io/?via=maximilian- TransparentShare: https://bit.ly/3laA6tK- SeekingAlpha*: https://www.sahg6dtr.com/QHJ7RM/R74QP/- Captrader*: https://www.financeads.net/tc.php?t=41972C46922130T DisclaimerAlle Informationen beruhen auf Quellen, die wir für glaubwürdig halten. Trotz sorgfältiger Bearbeitung können wir für die Richtigkeit der Angaben und Kurse keine Gewähr übernehmen. Alle enthaltenen Meinungen und Informationen dienen ausschließlich der Information und begründen kein Haftungsobligo. Regressinanspruchnahme, sowohl direkt, wie auch indirekt und Gewährleistung wird daher ausgeschlossen. Alle enthaltenen Meinungen und Informationen sollen nicht als Aufforderung verstanden werden, ein Geschäft oder eine Transaktion einzugehen. Auch stellen die vorgestellten Strategien keinesfalls einen Aufruf zur Nachbildung, auch nicht stillschweigend, dar. Vor jedem Geschäft bzw. vor jeder Transaktion sollte geprüft werden, ob sie im Hinblick auf die persönlichen und wirtschaftlichen Verhältnisse geeignet ist. Wir weisen ausdrücklich noch einmal darauf hin, dass der Handel mit Aktien, ETFs, Fonds, Optionen, Futures etc. mit grundsätzlichen Risiken verbunden ist und der Totalverlust des eingesetzten Kapitals nicht ausgeschlossen werden kann.Aussagen über zu erwartende Entwicklungen an Finanzmärkten, insbesondere Wertpapiermärkten und Warenterminbörsen, stellen NIEMALS EINE AUFFORDERUNG ZUM KAUF ODER VERKAUF VON FINANZINSTRUMENTEN dar, sondern dienen lediglich der allgemeinen Information. Dies ist selbst dann der Fall, wenn Beiträge bei wörtlicher Auslegung als Aufforderung zur Durchführung von Transaktionen im o.g. Sinne verstanden werden könnten. Jegliche Regressinanspruchnahme wird insoweit ausgeschlossen. *Affiliate-Link #Danaher #Aktie #Börse

You will never transform your company by point kaizen alone. Learn why traditional Japanese consultants were not enough in order to propel Danaher into a space all by themselves. Kaikaku (radical change) was a hallmark of Danaher's Strategy Deployment process.

It was a moment that would shape Erik Swenson's approach to finance forever. As a co-op student at Northeastern University, he found himself in front of a room full of engineers, presenting financial metrics he had carefully compiled. When the meeting ended, one of the engineers approached him and said, “That was interesting, but it doesn't mean anything to me. I make the product.” The comment struck a nerve. Driving home that evening, Swenson couldn't shake the realization—numbers alone don't drive a business; they need to connect to the people building it.That early lesson in financial storytelling set the foundation for a career built on bridging finance with operations. Swenson tells us his path wasn't a straight line—he originally pursued computer science before pivoting to economics and then accounting. After early roles in financial analysis, he spent 15 years moving through finance leadership positions at Danaher, where he sharpened his ability to translate financial insights into business decisions.When IDT tapped him to be CFO in 2018, Swenson faced a challenge that tested his adaptability. As he tells us, the company had a strong accounting foundation but needed deeper financial analysis to support its innovation-driven growth. He immediately set to work embedding finance into IDT's decision-making, ensuring the function wasn't just reporting numbers but helping shape the company's strategic direction. “It's not just about getting the numbers right,” Swenson explains, “it's about making sure those numbers mean something for the business.”

Mark discusses building profitability into the design process via the Target Costing methodology. Roughly 70% of a product's cost is baked into the product's design and process, leaving only 30% to Kaizen (post-design). Learn from Mark's experience as CFO of Danaher's JAKE Brake, where Target Costing played a significant role in JAKE's profitability.

This week we're talking to Dr. James Danaher about his newest book, "A Deeper Life". We talk about Jesus, the Gospel, and how the message of the Gospel isn't about becoming more righteous, but remembering and awakening to who we have always been. Enjoy! SHOW NOTES: JAMES DANAHER: https://www.amazon.com/stores/James-P.-Danaher/author/B001JS5LRY?ref=sr_ntt_srch_lnk_1&qid=1738764267&sr=8-1&isDramIntegrated=true&shoppingPortalEnabled=true A DEEPER LIFE: https://www.amazon.com/Deeper-Life-Mysticism-Jesus-Sermon-ebook/dp/B0D4R95WTN?ref_=ast_author_dp&dib=eyJ2IjoiMSJ9.kw8V28y42kAn1LFjLyYl72-LJ_vZ44lo1ci_s6fYLsbuk3otSoWXAgfnEtA5IuIYDrWbI-eBRrPnJtfbxEn6bsqW2HcNFvQefjesFQpdHmICDgSK8Elk2fA-DrgQ3wFts-os1HjpYPXVpO8BYPmeHw.kkb6W39IZBrmq-AUrrXw1J6J_XqosGnX8ou9C2aP6F0&dib_tag=AUTHOR MY BOOK: https://www.amazon.com/Emerging-Rubble-Stories-Shattered-Relationships/dp/B0C7T5TJD4/ref=sr_1_1?crid=2B051GGV2WCSI&keywords=glenn+siepert&qid=1700157759&sprefix=glenn+%2Caps%2C399&sr=8-1 SUBSTACK / BLOG: https://whatifproject.substack.com/ ART STUDIO: https://www.whatifproject.net/art SUPPORT THE SHOW: https://www.whatifproject.net/support SPECIAL MUSIC: FLYIN (Artist) / GO HIGHER (Song Name) / courtesy of epidemicsound.com

00:00 - 03:45 - How to get banned from IBJJF without steroids03:45 - 05:30 - Jiu Jitsu is gay 05:30 - 08:15 - Progression to full time training 08:15 - 10:25 - Building a social media following 10:25 - 13:20 - How to get better at competing 13:20 - 20:00 - How to structure a training schedule 20:00 - 25:20 - Training in Austin TX & Visas25:20 - 28:19 - Training with Danaher and why NW dominates 28:19 - 30:25 - IBJFF Worlds breakdown and upcoming comps30:25 - 33:00 - How to stop being fat33:00 - 34:00 - Going all in on BJJ34:00 - 39:00 - Social media will help you get more matches41:00 - 43:46 - Whats on for 2025 Where to find Seb: https://www.instagram.com/ebsayz/?hl=en Charles Strength Training Programs FREE 7 DAY PROGRAM:https://app.fitr.training/p/7dayfreeprogram 4 Week Jiu Jitsu Strength Program: https://app.fitr.training/p/4weekstrengthprogram Join The Team: https://app.fitr.training/p/matstrongonline BJJ Workouts Instructional: https://bjjfanatics.com/collections/new-releases/products/building-workouts-for-bjj-by-charles-allan-price 1:1 Coaching Inquiries: https://7kdbbkmkmsl.typeform.com/to/nSZHpCOL Hosted on Acast. See acast.com/privacy for more information.

On this episode of the Spot Radio Podcast, host Charlie Webb CPPL sits down with Elon Goldbaum from the Network Partner Group to delve into the intricacies of performing a Corrective and Preventive Action (CAPA). They discuss the framework that underpins the CAPA process, highlighting its crucial role in ensuring product quality and compliance in the medical device industry.Charlie and Elon explore the vital importance of the CAPA process, shedding light on how it helps organizations identify, address, and prevent potential issues. They also share valuable tips and strategies to make the CAPA process more manageable and effective, ensuring that businesses can maintain high standards of safety and quality.Tune in to gain insights from industry experts and learn practical advice that can be applied to your own CAPA initiatives. This episode is a must-listen for anyone involved in quality assurance, regulatory affairs, or medical device manufacturing.About our guest:As Vice President, Client Solutions for Network Partners Group, Elon (Lon) brings over 20 years of experience in the medical device field specializing in packaging, labeling, quality management systems, CAPA and sterilization. Lon's multifaceted background provides support and leadership to Network Partners' packaging consulting, quality assurance, labeling, and the Apprentice Leadership Program.Prior to joining Network Partners, Lon held various roles with Baxter Healthcare, Edwards Lifesciences, Endologix and Danaher with a wide range of responsibilities. Lon earned his Bachelor of Science degree in Packaging from Michigan State University.Elon Goldbaum e-mail: elon.goldbaum@onenpg.com

Jim and Jeff discuss the positive outlook for this cybersecurity stock. They also discuss why they sold this life sciences stock. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

APAC stocks traded higher following the positive handover from Wall St where tech clawed back some of the DeepSeek-related losses.European equity futures indicate a positive open with Euro Stoxx 50 future up 0.8% after the cash market closed with gains of 0.1% on Tuesday; boosted by pre-market earnings from ASML.DXY is a touch lower, JPY, EUR and GBP are all marginally firmer vs. the USD, AUD lags post-CPI.Microsoft (MSFT) is probing if a DeepSeek-linked group improperly obtained OpenAI data, according to FT.Looking ahead, highlights include Spanish GDP (Q4), US Advance Goods Trade Balance, NZ Trade Balance, Fed, BoC, Riksbank & BCB Policy Announcements, Fed Chair Powell, BoC's Macklem & Rogers, Riksbank's Thedeen, BoE Governor Bailey, Supply from UK & Germany, Earnings from ASML, Volvo AB, Santander, Tesla, Meta, Microsoft, IBM, T-Mobile, Danaher, General Dynamics & VF Corp.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

European bourses mostly firmer, with Tech surging after blockbuster ASML bookings; NQ slightly outperforms.USD is a little firmer ahead of the FOMC, CAD awaits BoC, AUD softer post-CPI.Bonds are bid into the FOMC. BTPs & OATs attentive to domestic matters.Crude slides and metals trade mixed ahead of FOMC.Looking ahead, US Advance Goods Trade Balance, NZ Trade Balance, Fed, BoC, & BCB Policy Announcements Speakers including Fed Chair Powell, BoC's Macklem & Rogers, BoE Governor Bailey, Earnings from Tesla, Meta, Microsoft, IBM, ServiceNow, T-Mobile, Danaher, General Dynamics & VF Corp.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Im zweiten Teil des 7+3-Gesprächs von Tobias Kramer mit Matthias Schmidt geht's um die größte Aktienposition von Matthias nach den echtgeld.tv-Kriterien (mehr als 100 Mio. € Market Cap und über 100.000 € tägliches Handelsvolumen der Aktie). Außerdem sind zwei Unternehmen aus dem Kreise deutscher Nebenwerte mit dabei, die Tobias bereits in seinem echtgeld.tv-Depot hält:

Before we turn the page on 2024, we wanted to shine one more light on the man behind our most popular class of the last year. And that's Mitch Rales, co-founder of Danaher, one of the most impressive businesses to have been built anywhere in the world this past century. Having co-founded Danaher 40 years ago alongside his brother and best friend Steve, the Rales boys have strung together a track record of compounding that might even make Buffett blush. Consider that Danaher has annualized at over 21% for four decades, resulting in an 1800-times multiple on invested capital! You'll learn from Mitch about the key inputs to his outlier success: why greatness is a journey that takes an unusual time horizon, the role benchmarking plays in standing up any winning organization, why it is essential to cultivate learning agility and embrace transformational pivots over time, and also the qualities Mitch looks for both in the leaders and businesses he looks to support. While Mitch is a natural teacher, this is actually his first recorded, long-form interview of any kind, and so we feel especially honored to share with you our candid conversation with someone who has shaped and transformed us and the business world in so many positive ways. Please enjoy today's class with Mitch Rales. For the full show notes, transcript, and links to mentioned content, check out the episode page here. ----- Joys of Compounding is a property of Pine Grove Studios in collaboration with Colossus, LLC. For more episodes of Art of Investing, visit joincolossus.com/episodes.  Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Show Notes (00:00:00) - Welcome to Joys of Compounding (00:04:32) - The Philosophy Behind Glenstone's Creation (00:11:57) - Benchmarking and Continuous Improvement: Lessons from Danaher and Glenstone (00:20:22) - The Influence of Mitch's Father and Upbringing (00:27:43) - Transforming Danaher During The George Sherman (00:29:39) - Embracing Long-Term Vision and Patience (00:35:47) - The Role of Leadership in Navigating Change (00:41:21) - Danaher's Evolutionary Journey: From 1.0 to 4.0 (00:55:37) - Building a Culture of Internal Growth and External Innovation (00:57:42) - The Art of Successful Acquisitions and Integration Strategies (01:02:03) - Seeking Leadership Qualities and Business Traits for Long-Term Success (01:05:14) - The Journey from Personal Experience to Philanthropy (01:12:10) - Investment Philosophy: Concentration vs. Diversification (01:28:46) - Operational Expertise as a Catalyst for Company Growth (01:33:17) - Identifying and Supporting Talent in Business (01:42:02) - The Impact of Secular Trends on Long-Term Investments (01:48:53) - Revitalizing the Washington Commanders (01:56:36) - Engaging with Fans and Building a Winning Culture (02:04:16) - The Importance of Long-Term Vision

"They're writing a constitution for the entire planet that will impact everybody, every biological system, every crop, and nobody knows anything about them because they operate in secret.." -Kevin Danaher, co-founder of Global Exchange and anti-WTO organizer On November 30th, 1999, a huge movement spanning labor, environment, human rights, fair trade and more literally shut down the World Trade Organization in Seattle. It was milestone in the growing anti-corporate globalization movement and challenged the inevitability of neo-liberalism. In a new series of episodes, we're looking at the 25th anniversary of the "Battle in Seattle" talking with a number of people who participated in the organizing and its aftermath. In this episode, we talk with co-founder of Global Exchange and anti-WTO protest organizer Kevin Danaher. Bio// Dr. Kevin Danaher is a co-founder of Global Exchange (1988), co-founder of FairTradeUSA (1997), founder and Executive Co-Producer of the Green Festivals (2001-2013), founder of the Green Guardians, and is a lifelong educator. His 1983 PhD in sociology from the University of California at Santa Cruz was based on his dissertation, “The Political Economy of U.S. Policy Toward South Africa.” He was very active in the anti-apartheid movement. Dr. Danaher has published numerous articles and is the author and/or editor of thirteen books, including: The Green Festival Reader: Fresh Ideas from Agents of Change; and Building the Green Economy: Success Stories from the Grassroots. His most recent book, The Two Globalizations, is a free PDF download at kevindanaher.org. He has an article, “On Becoming Solutionaries,” in the May 2020 issue of The Solutions Journal. --------------------- Outro- "Green and Red Blues" by Moody Links// + Global Exchange (https://globalexchange.org/) + Kevin's website (https://www.kevindanaher.org/) Follow Green and Red// +G&R Linktree: ⁠⁠⁠https://linktr.ee/greenandredpodcast⁠⁠⁠ +Our rad website: ⁠⁠⁠https://greenandredpodcast.org/⁠⁠⁠ + Join our Discord community (https://discord.gg/uvrdubcM) +NEW: Follow us on Substack (https://greenandredpodcast.substack.com) +NEW: Follow us on Bluesky (https://bsky.app/profile/podcastgreenred.bsky.social) Support the Green and Red Podcast// +Become a Patron at https://www.patreon.com/greenredpodcast +Or make a one time donation here: ⁠⁠⁠https://bit.ly/DonateGandR⁠⁠⁠ Our Networks// +We're part of the Labor Podcast Network: ⁠⁠⁠https://www.laborradionetwork.org/⁠⁠ +We're part of the Anti-Capitalist Podcast Network: linktr.ee/anticapitalistpodcastnetwork +Listen to us on WAMF (90.3 FM) in New Orleans (https://wamf.org/) This is a Green and Red Podcast (@PodcastGreenRed) production. Produced Bob (@bobbuzzanco) and Scott (@sparki1969). Edited by Scott.

Consider These Top ESG Stocks! ESG fund ownership offers great insight into the best stocks to own for potential returns. By Ron Robins, MBA Transcript & Links, Episode 143, November 29, 2024 Hello, Ron Robins here. Welcome to this podcast episode 143 published November 29, 2024, titled “Consider These Top ESG Stocks!” It's presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript and links to content – including stock symbols and bonus material – on this episode's podcast page at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, and I don't receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal any investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief. Please go to this podcast's webpage for links to the articles and more company and stock information. ------------------------------------------------------------- Consider These Top ESG Stocks! (1) I'm beginning this podcast episode with a great article titled The Top Stocks Widely Owned by ESG Funds. It's by Frances Aufderheide and found on morningstar.com. Here are some quotes from the article. “We found five stocks owned exclusively by large-cap sustainable funds in the industrials, materials, and healthcare sectors. We describe them below, with insight from Morningstar analysts and Sustainalytics. Source: Morningstar Direct. Weights as of Oct. 31, 2024. Data as of Nov. 5, 2024. 1. Ecolab (ECL) Morningstar Rating: 2 Stars Morningstar ESG Risk Rating Assessment: 3 Globes Price/Fair Value: 1.14 Total Return Year to Date (Month-End): 24.75 ‘As the global leader in the cleaning and sanitation industry, Ecolab provides products that help its hospitality, foodservice, and life-sciences customers do laundry, wash dishes, maintain clean manufacturing environments, and ensure regulatory compliance. With unmatched scale and a solid razor-and-blade business model, Ecolab's competitive advantages are firmly in place.' ‘Ecolab's largest growth driver over the next decade will be the water business, which generates the majority of revenue in the industrial segment. During the quarter, water revenue grew 3% versus the prior-year quarter on an organic basis, excluding currency movements.' —Seth Goldstein, Morningstar Strategist 2. Agilent Technologies (A) Morningstar Rating: 4 Stars Morningstar ESG Risk Rating Assessment: 4 Globes Price/Fair Value: 0.91 Total Return Year to Date (Month-End): (5.76) Agilent provides instruments, software and services for laboratories. ‘Agilent offers differentiated technology that is protected by various intangible assets, including patents, copyrights, and trademarks. This portfolio of intellectual property and its innovation prowess in chosen fields keep competitors from directly copying its technology.' —Julie Utterback, Morningstar Senior Equity Analyst 3. Xylem (XYL) Morningstar Rating: 3 Stars Morningstar ESG Risk Rating Assessment: 3 Globes Price/Fair Value: 1.07 Total Return Year to Date (Month-End): 7.43 ‘Xylem is one of the leading water technology companies in the world. Its extensive portfolio spans a wide range of equipment and solutions for the water industry, including the transport, treatment, testing, and efficient use of water for public utilities as well as industrial, commercial, and residential customers. Xylem operates four business segments: water infrastructure, applied water, measurement and control solutions, and water solutions and services.' —Krysztof Smalec, Morningstar Equity Analyst 4. W.W. Grainger (GWW) Morningstar Rating: 1 Star Morningstar ESG Risk Rating Assessment: 4 Globes Price/Fair Value: 1.66 Total Return Year to Date (Month-End): 34.57 W.W. Grainger distributes maintenance, repair, and operations products to more than 4.5 million customers. ‘We've raised our fair value estimate for narrow-moat-rated Grainger by 12% to $660 per share as we've become more confident of the firm's ability to maintain long-term operating margin above 14%. Even so, the current stock price remains well above our revised fair value estimate.' ‘Our confidence (of a narrow moat) is rooted in Grainger's ability to fend off competitive pressures from both new and existing players in the maintenance, repair, and operations market.' —Brian Bernard, Morningstar Senior Director 5. Veralto (VLTO) Morningstar Rating: None Morningstar ESG Risk Rating Assessment: 3 Globes Total Return Year to Date (Month-End): 24.56 Veralto provides technology solutions to improve the quality and reliability of water and product innovations through a suite of brands. ‘This tax-free spinoff is just the latest example of Danaher's business pruning.' —Julie Utterback, Morningstar Senior Equity Analyst” End quotes. Also, go to the link on this podcast page to this article for additional research on the “Top 10 widely held in US Sustainable Large-Cap Fund Universe” and “Top 5 Overweight Securities in the US Sustainable Large-Cap Fund Universe”. ------------------------------------------------------------- Consider These Top ESG Stocks! (2) The second article today reviews a company that is an old favorite of ethical and sustainable investors. The article is titled Buy First Solar Stock on the Dip. Solar Energy Will Be Too Good an Opportunity for President-Elect Trump to Pass Up. It's by James Brumley and found on fool.com. Here are a few of his comments on First Solar stock. “First Solar (FSLR) Investors suspect pro-oil President-elect Donald Trump could also prove unsupportive of renewable energy. In fact, most clean energy stocks are down since his Nov. 5 election on this very worry. First Solar has been no exception to the industrywide sell-off. This weakness, however, is also a buying opportunity for anyone interested in owning a piece of the solar panel maker, or in adding exposure to the solar industry as a whole. The solar power movement is too big and too well-developed for Donald Trump to bring to a halt now. First Solar is also well-positioned to sidestep one of the few meaningful actions the president-elect could take to disrupt the solar industry's growth. Solar is just too competitive to stop now Data gathered by Wood Mackenzie and reported by the U.S. Department of Energy indicates that utility-scale solar power is now in line with the cost of natural gas and coal-fired power… The irony? Largely because it's the cheapest means of adding utility-scale power production there, solar is growing like wildfire in several states like Texas, Oklahoma, and Kansas that picked Trump to be president during the recently ended election cycle. To the extent voters picked Trump for economic reasons, they'll certainly appreciate cheaper electricity and its positive impact on the economy. The 2022 passage of the Inflation Reduction Act is admittedly fueling much of this growth, by offering taxpayers a tax credit of up to 30% of the cost of a solar power system. The IRA also incentivizes utility-scale solar power projects as well as the manufacturing of solar panels themselves… But tariffs? While unspecific as well as far from being certain (Trump argues the mere threat of tariffs is enough), First Solar is mostly immune to their impact anyway. Although the company requires some imported materials that may be subject to such tariffs, it's an American manufacturer mostly serving the North American market, where the company believes over 90% of its immediate revenue opportunities await… Data source: StockAnalysis.com. Chart by author. Give at least partial credit for this brewing growth to First Solar's Cadmium Telluride (CdTe) photovoltaic panels. Although they make its design and production processes more complicated and more costly than that of more conventional silicon panels, this technology proves more durable while at the same time delivering more power. Utility-scale buyers are increasingly seeing these high-performance panels as an investment rather than an expense, as they further lower the effective per-kilowatt cost of solar power… The market's overestimating the risk, and underestimating First Solar Now all of a sudden First Solar's stumble since early November and its much bigger 37% pullback from June's peak looks like an entry opportunity. The analyst community agrees, anyway. Undeterred by political rhetoric and handwringing, most of them still consider First Solar stock a strong buy, sporting a consensus price target of $280.79. That's almost 50% above the stock's present price.” End quotes. ------------------------------------------------------------- Consider These Top ESG Stocks! (3) This next article, though from Australia, might interest many investors outside of that wonderful country. It's titled The Ethical Investor: These three ESG award-winning ASX companies show how it's done. It's by Eddy Sunarto found on ntnews.com.au. Here are some of what Mr. Sunarto says about his picks. “1. Orica (ASX:ORI) was named Australia's most sustainable company in the 2024 Australian Financial Review Sustainability Leaders awards, taking home top honours for its significant environmental impact. The company, a global leader in commercial explosives, was recognised for its groundbreaking emissions abatement project at its Kooragang Island plant near Newcastle, NSW. This project is the largest of its kind in the Australian chemicals sector, reducing emissions by 45% at the site and cutting national chemical industry emissions by 11%... The judges believe Orica's efforts have not only addressed environmental challenges but have also driven economic growth, injecting millions into the local economy while future-proofing critical manufacturing capabilities for industries such as mining, agriculture and healthcare. The company's commitment to sustainability is also reflected in its ambitious climate targets, aiming for net zero emissions by 2050. 2. Sims Metal Management (ASX:SGM) an Australian-based global recycling company with a 106-year history, was named the most sustainable corporation of 2024 by Corporate Knights, topping its Global 100 list. Known for its role in the circular economy, Sims has been integral in reducing carbon emissions by recycling metals like steel, copper, and aluminium – which are crucial in industries like electric vehicles, wind turbines and solar panels. In 2023 alone, the company's efforts saved 13 million tonnes of CO₂, equivalent to removing nearly three million cars from the road, according to its reports. Sims' approach to sustainability extends beyond recycling, with ambitious goals to transition to renewable energy in its operations by 2025 and achieve net-zero emissions by 2050… The company is investing in advanced technologies, like automated sorting systems and AI robots, to improve the efficiency of its recycling processes. Although these innovations may not always attract the same attention as large renewable energy projects, CEO Stephen Mikkelsen said that metal recycling plays a vital role in decarbonising industries and contributing to a sustainable future. 3. Australian Vintage (ASX:AVG) won the 2024 Global Drinks Intel ESG Award for Sustainable Wine Producer, which was announced in September. The award recognised the company's strong commitment to environmental, social, and governance (ESG) principles, despite current challenges within the Australian wine industry. The company had earlier achieved B Corp certification in February, making it one of only three Australian wine companies with this status. Australian Vintage's ESG strategy focuses on three key pillars: 'Thriving People', 'Nurture Nature', and 'Meaningful Growth'. The company said all these are supported by measurable, verifiable performance… The judges praised Australian Vintage for not just making ESG commitments, but for quantifying and achieving real, impactful results.” End quotes. ------------------------------------------------------------- Additional Articles of Interest 1. Title: The Top 10 Nuclear Energy Companies Shaping Clean Power on vaneck.com. By Coulter Regal. 2. Title: How to Get Fossil Fuels Out of Your Investment Portfolio on nytimes.com. By Tara Siegel Bernard. 3. Title: Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy' Stocks on finance.yahoo.com. By TipRanks. 4. Title: Top 10: Sustainable Brands on sustainabilitymag.com. By Jasmin Jessen. ------------------------------------------------------------- Ending Comment These are my top news stories with their stock and fund tips for this podcast “Consider These Top ESG Stocks!” Please click the like and subscribe buttons wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these troubled times! Contact me if you have any questions. Thank you for listening. Now my next podcast will be December 13th. I'll talk to you then! Bye for now.   © 2024 Ron Robins, Investing for the Soul

Why is everyone suddenly obsessed with water technology? When GE sold its water division in 2017, nobody blinked. But in 2024, Georg Fischer's stock jumped 15% when they announced they're selling everything BUT water! Plus GF's not alone: DuPont and Danaher are making similar moves, and there's a World in which Veolia might move along. What changed? Water tech companies are expected to grow from $290B to $1.4T in value by 2034. From being seen as "slow-growth" and "low-tech" a decade ago, water technology is now the hottest asset in industrial portfolios. Let's explore what this means for the future of the #WaterSector - and more precisely for #WaterTech companies! Get my friend Björn to buy me a beer (and pocket the 10% discount) subscribe to Global Water Intelligence using the code "BJOERN10" My Full Interview with Mads Joergensen (GF's CFO): https://www.youtube.com/watch?v=_Qg05MfjB7g My (impromptu) coverage of the Xylem/Evoqua Merger: https://www.youtube.com/watch?v=MrwKzgZYj5U

On this episode, we're joined by Alexis Montague and Alex TenPas from Danaher. Alex and Alexis discuss their internship experience, how Danaher supported them throughout their internship and describe why they chose to join Danaher as a full-time employee after graduating.

Jim and Jeff discuss Danaher beating Wall Street estimates for third-quarter profit and a solid start to earnings season. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Ever wonder what a Lean Investor thinks? What they see? The questions they ask? Probably not, since there are so few in existence. In this episode, Mark talks with his long-time friend and colleague of 34 years, Cliff Ransom, of Ransom Research. As a Wall Street Analyst, Cliff covered Danaher, starting in 1990 at their Jake Brake Division. He has dedicated his professional career to the understanding of Lean Thinking as it relates to investing and profitable growth. A life-long learner who has invested his own time on Shingijutsu Study Missions around the world, including Toyota Japan. Having grown up with Danaher, Cliff understands the growth and mindset that made Danaher the powerhouse it is today. Listen as you learn to see Lean through Cliff's eyes, as well as our discussion on the “next generation Danahers.”

In this episode we are talking all about integrating coaching, posiitve psychology and occupational therapy for enhanced mental health care. Padraig Danaher and I discuss:  Padraig is a senior occupational therapist and psychological coach specializing in trauma, sensory attachment, and positive psychology. Padraig has an extensive background in social care, with over 13 years of … 120 – Revolutionizing Mental Health: Blending Coaching, Positive Psychology and Occupational Therapy ft Padraig Danaher Read More »

Mark discusses why TOC was not included in the framework of DBS and how TOC is in conflict with fundamental Lean principles. In the final analysis, it was determined that TOC offered nothing unique when compared to Lean and had the potential to drive the wrong behaviors while creating mass confusion amongst Danaher companies.

The Accountability CEOScott Wine, has 16 years as CEO and top executive at major public companies like CNH, Polaris, UTC Fire and Security, Danaher, and Honeywell.He shares his proven approach for instilling accountability across organizations and teams at all levels. Just wait until you hear how this one strategy......delivered REMARKABLE results and success for thousands.Without accountability, even the strongest and most brilliant teams can fail.You know it when you see blame-shifting and missed opportunities.That's where Scott's powerful message comes in!Scott's LinkedIn Profile https://www.linkedin.com/in/scott-wine-bb67844What You'll Discover in this EpisodeWhy He Often Traveled by Horse and Buggy.Life Lesson from a CEO Father.What He Learned Running the Executive Dining Room for General Colin Powell..A Leadership Lesson in Cup of Coffee.Navy experiences, leadership lessons, and career advice.Teamwork and Accountability..Indian Motorcycles - Leading a Transformation.The Daily Activity that Boosts his Focus and Clarify.A Gadget that Contributed to his Success.-----Connect with the Host, #1 bestselling author Ben FanningSpeaking and Training inquiresSubscribe to my Youtube channelLinkedInInstagramTwitter

On this episode, we speak with Taina Adovelande from Danaher. Taina is the Internship Program Lead and discusses both of these programs, shares some feedback and success the programs have seen thus far and much more.

Allen Chilson, a recognized leader in the talent industry and frequent keynote and panelist speaker, joins Hiring University to talk about the importance of defining and defending company culture, AI pros and cons, and his win/loss prediction for his beloved Dallas Cowboys!  This is an episode you don't want to miss! "The last thing I want to do is totally rely on the data that I'm getting without having a conversation. Because if it's a fiercely competitive market to find the best people and you're throwing out those that are the outliers, you're missing a huge segment of the population. I think that is the risk and you're talking about some of the legal issues that the profiling and where the origin of the AI data is coming from that is going to get some people into trouble." - Allen ChilsonFor more Hiring University episodes tune into your favorite podcast player or visit us at www.ursusinc.com

Mark talks with Art Byrne, former Danaher executive and Wiremold CEO, about the early days at Danaher. Learn that it was more than the factory floor that had to change…more importantly, it was the mindset of Danaher's leadership. Art and Mark discuss the history of Jake Brake and Jacobs Chuck, the two early adopters of the Toyota Productions System, as led by the disciples of Taiichi Ohno, Shingijutsu Consulting, LTD. Little did Art know that we would be setting the stage for the adoption of Lean in the United States and beyond.

Padraig is a mental health occupational therapist, a positive psychology coach, and a trauma specialist. Selfishly I asked him to come on to my podcast so that I could benefit from our conversation and learn from him. The work he does around empowering people to accept their past, in order to take control of their future is phenomenal.  Our conversation did not disappoint. I loved it and could have chatted with him for hours. He is one of the most genuine people I have had the pleasure of meeting.  I had so many lightbulb moments throughout and have so many takeaways to implement going forward. I have no doubt that you'll get so much value from Padraig, and love this episode as much as I loved recording it.  His passion for what he does is undeniable and I can't wait to have him back on for another chat! Head over to Padraig's Instagram for more: https://www.instagram.com/the_ot_coach_/ 

Podcast Hosts: Grant Broggi: Marine Veteran, Owner of The Strength Co. and Starting Strength Coach. Jeff Buege: Marine Veteran, Outdoorsman, Football Fan and Lifter Tres Gottlich: Marine Veteran, Texan, Fisherman, Crazy College Football Fan and Lifter Join the Slack and Use code OKAY: https://buy.stripe.com/dR6dT4aDcfuBdyw5ks Check out BW Tax: https://www.bwtaxllc.com TIMESTAMPS: 00:00 - Olympics 04:11 - Vertical Jump 07:08 - Bulking 19:02 - Jeff and Tres Join 20:41 - Olympics Update 25:33 - New Jack White 29:11 - Lifting & Parent Update 36:05 - Shooting 44:16 - Placido Santos 53:04 - Jiu Jitsu Belts 57:21 - Rising Popularity of Jiu Jitsu 01:03:23 - MMA 01:06:34 - Best Self-Defense Martial Art 01:09:41 - Balancing Lifting & Jiu Jitsu 01:23:49 - Running A Gym 01:42:29 - How To Find A Good Jiu Jitsu Gym 01:44:07 - Placido Is OKAY 01:51:20 - Final Thoughts

Jim and Jeff discuss the smart plays by this life sciences stock. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

After a year and a half of the big names pushing the market forwards, some of the smaller companies are starting to go on a run.  (00:21) Bill Mann and Jason Moser discuss: - The Russell 2000s unusual spike, and why it's a mix of good news and bad news. - The Crowdstrike update that grounded planes and the stock this morning, and what it says about cybersecurity overall. - Earnings updates from Netflix, Domino's, and Five Below.  (19:10) Cava CEO Brett Schulman spoke at FoolFest 2024 this week – we air a portion of his conversation with analyst Kirsten Guerra about his company's stellar performance so far as a publicly traded company, how they'll get to 1,000 locations and what he puts in his bowl when he visits the restaurant. (33:56) Jason and Bill break down two stocks on their radar: Danaher and Alphabet. Stocks discussed: CRWD, AAPL, META, NFLX, DPZ, FIVE, DHR, GOOGL, GOOG Host: Dylan Lewis Guests: Bill Mann, Jason Moser, Kirsten Guerra, Brett Schulman Engineers: Steve Broido Learn more about your ad choices. Visit megaphone.fm/adchoices

What You'll Learn: In this episode, hosts Patrick Adams and Shayne Daughenbaugh discuss the implementation of Lean principles in accounting, emphasizing simplifying cost accounting, aligning costs with value streams, and adopting a PDCA mindset, while also noting the limitations of traditional practices and the need for a value-based approach. They covered Lean pricing strategies, such as market-based pricing and demand alignment, and discussed optimizing changeovers for efficiency, alongside sharing experiences of assisting veterans in their transition to civilian life. About the Guest:  Mark DeLuzio is Founder and Chief Executive Officer of Lean Horizons Consulting. He is also a former Corporate Officer and Vice President of Danaher Business System (DBS) for Danaher Corporation. Danaher has been recognized as the leading implementer of Lean globally and has been rated as the 3rd most profitable US stock over the last 30 years. Mark is also credited with developing the first Lean Accounting process in the United States for Danaher's Jake Brake Division, where he served as their Chief Financial Officer. Mark is the author of “Turn Waste into Wealth,” which offers practical advice for those considering a Lean transformation and “Flatlined – Why Lean Transformations Fail and What to do About It”, which offers the lessons learned from Mark's association with hundreds of Lean transformations on a global basis. Links: ⁠⁠⁠⁠Click Here For Patrick Adams LinkedIn⁠ ⁠Click Here For Shayne Daughenbaugh's LinkedIn Click Here For mark Deluzio's Website --- Support this podcast: https://podcasters.spotify.com/pod/show/leansolutions/support

Send us a Text Message.A man with no history of violence commits a particularly brutal murder.It was what he stole from the victim that proved to be his undoing.His attention to detail meant the police were able to gather a lot of evidence from his own electronic devices but didn't go as far as disposing of only half of the murder weapon.But why?  Was it a foul mouth rejection when asking for advice?  Or was it hatred and resentment of someone succeeding when he couldn't?...This week we talk about: Murder, Auctions, Banksy, JK Rowling, Hit List, Oxford, PeterboroughSources:https://en.wikipedia.org/wiki/Adrian_Greenwoodhttps://www.amazon.co.uk/stores/author/B00W5RBKKA/about?ingress=0&visitId=1bb5e489-c4eb-43c2-a98f-cb3c00f6c36ehttps://find-and-update.company-information.service.gov.uk/company/07178351https://www.bbc.co.uk/news/uk-england-oxfordshire-13142066https://www.artsy.net/artwork/banksy-rats-on-safe-2https://www.huffingtonpost.co.uk/entry/the-wind-in-the-willows-murder-what-drove-michael-danaher-to-kill-adrian-greenwood_uk_59639426e4b02e9bdb0e4eefhttps://www.bbc.com/news/uk-england-oxfordshire-37546448https://www.theguardian.com/uk-news/2016/oct/04/michael-danaher-murder-trial-adrian-greenwood-kate-mosshttps://www.theguardian.com/uk-news/2016/oct/24/man-found-guilty-murdering-rare-books-dealer-wind-in-the-willows-oxford-adrian-greenwoodhttps://www.dailymail.co.uk/news/article-4680208/Gentle-giant-ex-husband-murdered-Oxford-bookseller.htmlhttps://oxfordshireguardian.co.uk/killer-sentenced-to-life-for-murdering-oxford-bookseller/https://www.dailymail.co.uk/news/article-3867336/Michael-Danaher-50-guilty-murdering-historian-book-dealer-Adrian-Greenwood.htmlSupport the Show.Patreon https://www.patreon.com/MMoMEmail: murdermeonmondaypodcast@gmail.com Twitter: https://twitter.com/MMonMonday Instagram: https://www.instagram.com/murdermeonmondaypodcast/ Theme Tune is published under license from: Tribe of Noise – Awkward Mystery https://prosearch.tribeofnoise.com/artists/show/29267/32277

On this episode, we speak with Norman Jones from Danaher. Norman is the Director of Global University Recruitment and introduces their company, the different University Programs they run and much more.

We are excited to share a great conversation with Mitch Rales, the co-founder of Danaher and one of the living legends in the world of business and investing. Consider that Danaher has annualized at over 21% for four decades, resulting in an 1800-times multiple on invested capital! This is Mitch's first long-form interview of any kind, and he covers his entire history and business philosophy. Interviewing Mitch are Paul Buser and Rick Buhrman, who host the Art of Investing podcast on the Colossus network. Please enjoy this comprehensive discussion with Mitch Rales. Listen to more Art of Investing. For the full show notes, transcript, and links to mentioned content, check out the episode page here. ----- This episode is brought to you by Passthrough. If you've ever filled out a subscription document to invest in a fund or worked with LPs to fill out their docs to invest in your fund, you know what a nightmare this exercise can be. Passthrough finally solves this problem. They configure custom workflows for your electronic subscription agreements and KYC & AML requirements to shrink the time for your investors to complete their sub docs. It's the best way to manage a critical part of your relationship with your LPs and is simply a drastically better experience for both investing firms and LPs alike. To learn more, go to passthrough.com. This episode is brought to you by Tegus, the only investment research platform built for fundamental investors. Whether you're trying to get up to speed on a new market or keep tabs on a portfolio company, Tegus is the end-to-end investment research platform you need. With Tegus, you can quickly understand a company's business model, drivers, benchmarks, and management quality. To monitor an entire market, download our pre-built financial models — or update your own with the latest data using Tegus' new Excel Add-In. Tegus gives you all of this and more, all bundled into a single software license. Find out why 95% of the top 20 global private equity firms are Tegus customers. Learn more and get your free trial at tegus.com/patrick. ----- Art of Investing is a property of Pine Grove Studios in collaboration with Colossus, LLC. For more episodes of Art of Investing, visit joincolossus.com/episodes.  Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Show Notes (00:00:00) - Welcome to The Art of Investing (00:05:32) - The Philosophy Behind Glenstone's Creation (00:12:57) - Benchmarking and Continuous Improvement: Lessons from Danaher and Glenstone (00:21:22) - The Influence of Mitch's Father and Upbringing (00:28:43) - Transforming Danaher During The George Sherman (00:30:39) - Embracing Long-Term Vision and Patience (00:36:47) - The Role of Leadership in Navigating Change (00:42:21) - Danaher's Evolutionary Journey: From 1.0 to 4.0 (00:56:37) - Building a Culture of Internal Growth and External Innovation (00:58:42) - The Art of Successful Acquisitions and Integration Strategies (01:03:03) - Seeking Leadership Qualities and Business Traits for Long-Term Success (01:06:14) - The Journey from Personal Experience to Philanthropy (01:13:10) - Investment Philosophy: Concentration vs. Diversification (01:29:46) - Operational Expertise as a Catalyst for Company Growth (01:34:17) - Identifying and Supporting Talent in Business (01:43:02) - The Impact of Secular Trends on Long-Term Investments (01:49:53) - Revitalizing the Washington Commanders (01:57:36) - Engaging with Fans and Building a Winning Culture (02:05:16) - The Importance of Long-Term Vision

Today, we cover the industrial conglomerate AMETEK. This is one of eight companies that Mark Leonard and his team at Constellation Software studied as they built their own empire. And it's one well worthy of a discussion as you'll hear.  To break down AMETEK, I'm joined by Nael Fakhry, Co-CIO of the Osterweis Capital Management Growth and Income Strategy. Nael has spent a significant amount of time around AMETEK from the early 2000s until today. Please enjoy this breakdown on AMETEK. Listen to Mitch Rales talk about Danaher on Art of Investing. Interested in hiring from the Colossus Community? Click here. For the full show notes, transcript, and links to the best content to learn more, check out the episode page here. ----- This episode is brought to you by Public: Invest in stocks, bonds, options, crypto, and more in one place. A High-Yield Cash Account is a secondary brokerage account with Public Investing, member FINRA/SIPC. Funds from this account are automatically deposited into partner banks where they earn a variable interest and are eligible for FDIC insurance. Neither Public Investing nor any of its affiliates is a bank. US only. Learn more at public.com/disclosures/high-yield-account. This episode is brought to you by Tegus, the only investment research platform built for the investor. With traditional research vendors, the diligence process is slow, fragmented, and expensive. That leaves investors competing on how well they can aggregate data — not on their unique ability to analyze insights and make great investment decisions. Tegus offers an end-to-end platform with all the data you need to get up to speed on a company or market: up-to-the-minute financials, customizable models, management and culture checks, and, of course, our vast and growing library of expert call transcripts. Tegus is changing the world of expert research. Learn more and get your free trial at tegus.com/patrick. ----- Business Breakdowns is a property of Colossus, LLC. For more episodes of Business Breakdowns, visit joincolossus.com/episodes. Stay up to date on all our podcasts by signing up to Colossus Weekly, our quick dive every Sunday highlighting the top business and investing concepts from our podcasts and the best of what we read that week. Sign up here. Follow us on Twitter: @JoinColossus | @patrick_oshag | @zbfuss | @ReustleMatt | @domcooke Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Show Notes (00:00:00) Partners (00:01:40) Welcome to Business Breakdowns (00:03:52) An Overview of Ametek (00:05:17) Ametek's Diverse Product Range  (00:12:09) Ametek's history: From Bankruptcy to Industrial Dominance (00:21:22) Ametek's Growth Model: Innovation, Acquisitions, and Global Expansion (00:26:23) Understanding Ametek's Finances (00:30:37) Exploring Revenue Growth and Margin Expansion (00:31:10) Incremental Margins and Cyclical Nature of the Business (00:32:07) Operational Excellence (00:34:35) Decentralized Approach (00:36:21) The Role of Acquisitions (00:37:33) Challenges and Risks (00:39:45) Capital Allocation (00:46:55) Evaluating Cyclical Business Performance and Resilience (00:49:27) Dividend Policy (00:50:44) Valuation and Growth Sustainability (00:54:41) Key Lessons Learn more about your ad choices. Visit megaphone.fm/adchoices

Today's teacher is Mitch Rales, one of the most iconic business builders and philanthropists of our time. Consider that Danaher has annualized at over 21% for four decades, resulting in an 1800-times multiple on invested capital! You'll learn from Mitch about the key inputs to his outlier success: why greatness is a journey that takes an unusual time horizon, the role benchmarking plays in standing up any winning organization, why it is essential to cultivate learning agility and embrace transformational pivots over time, and also the qualities Mitch looks for both in the leaders and businesses he looks to support. While Mitch is a natural teacher, this is actually his first recorded, long-form interview of any kind, and so we feel especially honored to share with you our candid conversation with someone who has shaped and transformed us and the business world in so many positive ways. Please enjoy today's class with Mitch Rales. For the full show notes, transcript, and links to mentioned content, check out the episode page here. ----- This episode is brought to you by Summus. Summus is a revolutionary health benefits solution, driving superior employee engagement while dramatically lowering your company's enterprise-level healthcare spend. They're completely transforming the world of health benefits by providing employers and their employees in any location, fast access to over 5,100 of the top medical specialists from America's very best medical centers for support across all health questions. If you're looking for a benefit that drives your employee engagement, truly takes care of your people in their most scary and vulnerable times, all while improving your healthcare ROI, visit GoSummus.info/AOI. This episode is brought to you by Hunt Club. Hunt Club unlocks relationships and helps companies grow. Whether it's recruiting your next hire, landing your next big partner, or financing your business, a trusted introduction always works more effectively. Hunt Club's tech-enabled search model leverages the largest community of its kind to refer amazing talent on your behalf. Additionally, its software program, Atlas, helps organize the entire network of a company or fund and assists in streamlining the right introductions. If you're looking for the ideal solution for all of your talent needs, visit HuntClub.com/AOI. ----- Art of Investing is a property of Pine Grove Studios in collaboration with Colossus, LLC. For more episodes of Art of Investing, visit joincolossus.com/episodes.  Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Show Notes (00:00:00) Welcome to The Art of Investing (00:04:32) The Philosophy Behind Glenstone's Creation (00:11:57) Benchmarking and Continuous Improvement: Lessons from Danaher and Glenstone (00:20:22) The Influence of Mitch's Father and Upbringing (00:27:43) Transforming Danaher During The George Sherman (00:29:39) Embracing Long-Term Vision and Patience (00:35:47) The Role of Leadership in Navigating Change (00:41:21) Danaher's Evolutionary Journey: From 1.0 to 4.0 (00:55:37) Building a Culture of Internal Growth and External Innovation (00:57:42) The Art of Successful Acquisitions and Integration Strategies (01:02:03) Seeking Leadership Qualities and Business Traits for Long-Term Success (01:05:14) The Journey from Personal Experience to Philanthropy (01:12:10) Investment Philosophy: Concentration vs. Diversification (01:28:46) Operational Expertise as a Catalyst for Company Growth (01:33:17) Identifying and Supporting Talent in Business (01:42:02) The Impact of Secular Trends on Long-Term Investments (01:48:53) Revitalizing the Washington Commanders (01:56:36) Engaging with Fans and Building a Winning Culture (02:04:16) The Importance of Long-Term Vision

Jim and Jeff discuss the comeback of this health-care stock. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake  CNBC Investing Club Disclaimer

On episode #163, I spoke with the Fr. Timothy Danaher, OP, about effective evangelization.During our conversation, we covered:- De Montfort and his criticism of poor preaching- The role of the priest- The role of the lay faithful regarding preaching- And much more...Biography:Fr. Timothy Danaher, O.P. grew up in Steubenville, OH, where he attended Franciscan University, studying American Literature and Theology. He is a Dominican friar and was ordained in 2018 in Washington D.C. after graduate studies and ministry focused on hospital and Hispanic settings. Before arriving at AQ, he served for three years at St. Patrick's Church in Philadelphia, PA. His favorite color is blue. Quotes:“But the words that divine Wisdom communicates are not just ordinary, natural, human words; they are divine, "truly the words of God."They are powerful, touching, piercing words, "sharper than a two-edged sword," words that go from the heart of the one through whom he speaks straight to the heart of the lis. tener. Solomon is referring to this gift of Wisdom he himself had received when he said that God gave him the grace to speak according to the feelings of his heart. These are the words which our Lord promised to his apostles, "I will give you an eloquence and a wisdom that none of your adversaries will be able to resist."How few preachers there are today who possess this most wonderful gift of eloquence and who can say with St. Paul, "We preach the wisdom of God." Most of them speak according to the natural light of their minds, or from what they have taken from books.They do not speak under the impulse of divine Wisdom or from a heart filled to overflowing with wisdom. That is why in these times we see so few conversions made through preaching. If a preacher had truly received from Eternal Wisdom this gift of eloquence, his listeners would hardly be able to resist his words, as happened in the early days of the Church: "They could not resist the wisdom and the Spirit speaking in him." Such a preacher would speak with so much unction and such authority that his words could never be ineffectual and void.” St. Louis Marie de MontfortOur Sponsors:This is a Good Catholic Podcast.  If you're interested in purchasing a Good Catholic digital series, use code GBS for 20% off your total order.Looking for the perfect Catholic gift? Check out The Catholic Company and find it today! Use code SAINTS20OFF for 20% off your next purchase! Support the show

Brett Cornell is the Senior Vice President of Tax, Treasury & Finance at Danaher Corporation. In this episode of On Tax, he and Cravath partner and host Len Teti talk about how Brett's early interest in accounting led him to tax positions at several global companies. They also discuss the broader responsibilities of his current role and the importance of tax across business functions. Hosted on Acast. See acast.com/privacy for more information.